Chinese drug research firms are altering project plans, stockpiling supplies, and considering testing locally to soften the blow of US-China trade tensions, Reuters reported Wednesday, citing sources with knowledge of the matter.
Companies such as WuXi AppTec (HKG:2359, SHA:603259) and WuXi Biologics (HKG:2269) help pharmaceutical giants such as Pfizer and AstraZeneca with their research through the use of imported clinical samples, equipment, and chemicals, Reuters said.
Apprehensions regarding difficulties of accessing US supply chains are driving Chinese biotech firms to avoid, pause, or delay project start times, the report said.
Chinese firms are also mulling testing US clinical samples in the US instead of sending them to China for further studies, although that could raise costs, Reuters reported, citing the sources.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.